BIOSPAIN 2026: Full Schedule

14:30 CEST

Spanish biotech spin-offs and their integration into the global ecosystem: reaching out and attracting EU, US and Asia players.

Tuesday September 29, 2026 14:30 - 15:15 CEST

4 Raúl Martín room

Spanish biotech spin-offs are stepping onto the global stage like nimble launchpads of innovation, pulling in investors and partners from Europe, the US and Asia. Rooted in world-class science yet built for translation, they marry academic brilliance with entrepreneurial grit — and with sharper international branding, smoother regulatory pathways and bolder cross-border alliances, they can turn local discoveries into scalable, globe-spanning solutions.

Speakers

Emilio Erazo Fischer

Operating Partne, Asabys Partners

Operating partner at Asabys, Emilio joined the team in December 2024. Emilio supports our biopharma portfolio investments in strategy and business development and currently holds the CBO role at ALLOX.Previously, Emilio led external innovation deals at Boehringer Ingelheim, as Director of Global BD&L Oncology, contributing novel pipeline assets and technology platforms. Emilio has fostered pharma-biotech relationships across Europe, the US and Japan, and served as consultant for... Read More →

Tuesday September 29, 2026 14:30 - 15:15 CEST
4 Raúl Martín room

Round table discussion

Audience English language
Subject Call for sessions, Asabys Partners
Track Finance & investment

15:15 CEST

Current innovation trends in therapeutic technologies and modalities: what is the potential of Spain to ride these waves?

Wednesday September 30, 2026 15:15 - 16:00 CEST

2 Dorotea Barnés room

A guided tour of Spain’s biomedical frontier: where tomorrow’s therapies are being born, who’s driving them, which technologies enable them, and how to convert those breakthroughs into investment and company-building opportunities

Moderators

Montserrat Vendrell

Partner, Asabys Partners

Montse currently serves on the board of directors of Ona Therapeutics, InBrain Neuroelectronics, Peptomyc and Accure. She is also independent director at the board of Oryzon genomics.Formerly, Montse was partner at Aliath Bioventures and Alta Life Sciences. Prior to that, she was... Read More →

Speakers

Robert Fabregat

General Manager, Biocat - Catalan Bioregion

Robert Fabregat (Barcelona, 1980) holds a degree in Chemistry and a PhD in Pharmacy from the University of Barcelona (UB), as well as a Master’s degree in Project Management from BES-La Salle and specific training in Strategy and Innovation from ESADE. From 2019 to 2021, he was... Read More →

Gurutz Linazasoro

Neurólogo / Fundador, VIVEbiotech

Gurutz es neurólogo especializado en enfermedad de Parkinson y trastornos neurodegenerativos. Es Director del Programa de Terapias Avanzadas para el Alzheimer y Parkinson del Grupo Quirón Salud-Policlínica Gipuzkoa, y Director del Curso Nacional Anual sobre Trastornos del Movimiento.Gurutz... Read More →

Gloria González

CIMA, investigadora-Directora de Innovación / CSO en VIVET, Venture partner de Asabys, CIMA

Directora de programa Terapia Génica de Enfermedades Raras.
Investigadora principal del grupo Terapias Avanzadas para Enfermedades Hepáticas Raras.
Dedicación preferencial a la terapia génica enfermedades hepáticas, modelos animales de enfermedades hepáticas.

Moisés Martín Carretero

Director General, CDTI

José Moisés Martín Carretero university degree in economics from the Universidad autónoma de Madrid and has extended graduate programs in finance from the IE Business School, Economic Analysis in the national and international economic relations in the CEPADE from Universidad... Read More →

Wednesday September 30, 2026 15:15 - 16:00 CEST
2 Dorotea Barnés room